Celaid Therapeutics Inc.
As of May 2024
| City | Year of Establishment | Founder |
|---|---|---|
| Bunkyo-ku, Tokyo | 2020 | Nobuyuki Arakawa |
| Partner VC | Latest round of Fundraising | Valuation |
|---|---|---|
| The University of Tokyo Edge Capital Partners (UTEC) | Series A extension | Non-Disclosure |
- Contact Information : contact@celaidtx.com
- Website :
Celaid Therapeutics Inc.
Program name
Deep-Tech Startups Support Program
Research theme
R&D Cost of HSC Expansion Platform Technology for Cell and Gene Therapy Companies
Business Plan
Celaid will establish and validate systems for supplying clinical and commercial-grade HSC expansion methods and culture media to the biotechnology field enabling global biotech/pharmaceutical companies to address their technical challenges encountered in commercial manufacturing of cell and gene therapy products.
Research Outline
Through this R&D effort, clinical and commercial-grade HSC expansion methods and culture media will be established (R&D #1&2). In parallel, experiments on the application of HSC expansion technology to cell and gene therapy products will be conducted (R&D #3&4).
- R&D #1. Establishment of clinical-grade culture media
- R&D #2. Development of HSC expansion manufacturing process
- R&D #3. Application to the manufacturing process of ex vivo gene therapy products
- R&D #4. Application to the manufacturing process of cell therapy products
| Phase | Business Area/Field | Research Period | Research Grant Amount |
|---|---|---|---|
| STS | Healthcare | 2024 - 2025 FY | JPY 199 million |
International collaborative technology demonstration
| Countries/Regions | Collaborative activity outline |
|---|---|
| Japan, United States, Europe etc. | - |
Download this pageLast Updated : June 6, 2024